# A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05382442/  
OnCo record `nct05382442` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ivonescimab, AK117, CAPOX in colorectal cancer, run by Akeso, active and no longer recruiting.

## Summary

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT05382442 by Akeso, with 254 participants planned, started 2022-06-27 and due to reach its primary completion in 2026-05-15. Interventions recorded: AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05382442
- Phase: 2
- Setting: A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer
- Sponsor: Akeso
- Enrolled: 254

## Sources

- ClinicalTrials.gov NCT05382442: https://clinicaltrials.gov/study/NCT05382442

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [AK117](https://onco.cc/drugs/ak117/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05382442.json